---
title: Gilead Sciences (GILD) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/gild
ticker: GILD
as_of: 2026-10-17
sector: Healthcare
industry: Drug Manufacturers - General
---
# Gilead Sciences (GILD)

Gilead Sciences (GILD) closed at $156.19 on Oct 16, 2026, undervalued by 16% vs its model value of $186.82 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $156.19 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $186.82 |
| Price vs model | undervalued by 16% vs model |
| Range of that model | $111.96 – $551.88 |
| Market value | $193.7B |
| P/E (fiscal 2025) | 23.0 |
| Net margin (fiscal 2025) | 28.9% |
| Free cash flow (fiscal 2025) | $9.5B |
| Dividend yield (trailing twelve months) | 2.08% |
| Beta | 0.33 |
| Cost of capital (WACC) | 7.04% |
| Business classification | Dividend Payer (Low/slowing growth (~4% recent), High profitability (29% net margin), Pays dividends, Highly cyclical earnings) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Near 52-week highs | #31 | −0.7% | https://sweetvaluelab.com/lists/near-52-week-highs |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 2.08% |
| Dividends per share, last 12 months | $3.25 |
| Dividends / free cash flow (fiscal 2025) | 42.3% |
| Raised | 10+ years in a row |
| Growth over 5 years | 3.0% a year |
| Latest payment | $0.82, ex-date Sep 15, 2026, paid Sep 29, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Sep 14, 2021 | $2.81 |
| To Sep 14, 2022 | $2.90 |
| To Sep 14, 2023 | $2.98 |
| To Sep 13, 2024 | $3.06 |
| To Sep 15, 2025 | $3.14 |
| Trailing twelve months (to Sep 15, 2026) | $3.25 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $186.82 | $111.96 | $551.88 |
| DCF · Perpetuity growth · 10y | cross check | $205.77 | $126.64 | $586.46 |
| DCF · EBITDA exit · 5y | cross check | $178.03 | $126.22 | $239.11 |
| DCF · EBITDA exit · 10y | cross check | $197.72 | $138.25 | $277.03 |
| P/E · peers | cross check | $167.99 | $135.21 | $369.79 |
| P/E · own history | cross check | $139.81 | $110.74 | $160.28 |
| PEG | sanity check | $163.20 | $163.20 | $163.20 |
| EV/EBITDA · peers | cross check | $161.83 | $135.65 | $269.39 |
| EV/Revenue · peers | cross check | $152.58 | $118.33 | $255.32 |
| Earnings power value | cross check | $71.03 | $56.12 | $94.01 |
| Dividend discount | cross check | $78.82 | $51.08 | $146.89 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 16 open-market sales ($9.1M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 15, 2026 | Dickinson Andrew D | Chief Financial Officer | Open-market sell (10b5-1 plan) | 3,000 | $468,660 |
| Oct 15, 2026 | Mercier Johanna | Chief Comm & Corp Aff Officer | Open-market sell (10b5-1 plan) | 3,000 | $468,660 |
| Oct 1, 2026 | O'Day Daniel Patrick | Chairman & CEO | Open-market sell (10b5-1 plan) | 3,000 | $445,879.5 |
| Oct 1, 2026 | O'Day Daniel Patrick | Chairman & CEO | Open-market sell (10b5-1 plan) | 12,000 | $1.8M |
| Sep 22, 2026 | Burkhart Erin | SVP, Controllership | Option/RSU exercise | 2,223 | — |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 6, 2026 | S-3ASR | Shelf registration (automatic) | https://www.sec.gov/Archives/edgar/data/882095/000110465926092110/tm2621295-1_s3asr.htm |
| Aug 6, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm |
| Aug 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/882095/000088209526000028/gild-20260804.htm |
| May 20, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/882095/000110465926064518/tm2615045d1_8k.htm |
| May 18, 2026 | 424B5 | Prospectus supplement | https://www.sec.gov/Archives/edgar/data/882095/000110465926063199/tm2531124-2_424b5.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Dodge & Cox | 2026-06-30 | 23,677,567 | $3.0B |
| Bridgewater | 2026-06-30 | 290,881 | $36.7M |
| John Rogers | 2026-06-30 | 195,657 | $24.7M |
| Mairs & Power | 2026-06-30 | 2,275 | $287,424 |

4 tracked managers in all.

## About

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy…

---

Source: https://sweetvaluelab.com/stocks/gild (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.